SOMERSET, N.J., Aug. 9, 2018 /PRNewswire-PRWeb/ -- Catalent Pharma Solutions, the leading global provider of advanced
Mr. Hepler's presentation, on Thursday, Aug. 16 at 2:55 p.m., is entitled "Solutions for Automation of GMP Assays," and will include several case studies highlighting the benefits of assay automation and detailing strategies to overcome challenges. Mr. Hepler will also explore future directions in automation, which are being explored at Catalent Biologics. Attendees will learn:
Mr. Hepler is a 20-year veteran of the pharmaceutical and biopharmaceutical industry, and has extensive validation and project management experience operating under Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). He has expertise in protein purification, biochemical assays and laboratory automation. He holds a bachelor's degree in animal science and a master's degree in physiology, both from North Carolina State University.
For more information visit Catalent.com/IDDST.
To arrange a meeting with any of the attending Catalent executives at the event, contact Richard Kerns at NEPR - firstname.lastname@example.org
About Catalent Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™
SOURCE Catalent Pharma Solutions
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All